PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJETI.L Regulatory News (JETI)

  • There is currently no data for JETI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Company Update

20 Oct 2021 07:00

RNS Number : 5837P
JPMorgan European Invest Tst PLC
20 October 2021
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO, THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL.

 

The information communicated in this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this information is considered to be in the public domain.

 

 

JPMorgan European Investment Trust Plc

Company Update

Legal Entity Identifier: 549300D8SPJFHBDGXS57

 

20th October 2021

 

The Board of JPMorgan European Investment Trust Plc (the "Company") stated in its annual report for the financial year ended 31 March 2021 that it was continuing to work with its investment manager, JPMorgan Asset Management (UK) Limited (the "Investment Manager"), to determine whether the Company provides a model which will provide a sustainable attractive return for the longer term.

The Board has now concluded a review of the Company and its strategy, which included considering various options to improve marketability and to broaden the appeal of the Company as well as to improve liquidity and to narrow the discount at which the Company's shares trade. The Board believes there remains a strong case for investment in Europe, with the broad universe of European equities providing quality diversification for UK investors. However, the Board is of the view that the Company's existing dual share class structure is unnecessarily complex and potentially presents a hurdle to those looking to invest. The Board believes that a single share class with a clearly defined investment process would enable a cogent investment approach and increase the Company's appeal.

The Board has therefore determined that it would be in the best interests of shareholders to consolidate the Company's Income Shares and Growth Shares into a single class of ordinary shares (the "New Ordinary Shares") (the "Consolidation"). The investment objective and investment policy of the New Ordinary Shares will be the same as that of the Company's Growth Shares, reflecting the Board's confidence in the Investment Manager's strength and depth of team, as well as its track record, which has performed strongly against the Company's benchmark and peers over the last 2 years being a particularly challenging period for active managers. Looking longer term, the Company has also outperformed its benchmark over 5 and 10 years.

The Consolidation will create a company with net assets of approximately £500m and should ensure the critical mass needed to attract investors - it is also expected that the increased size will have a beneficial impact on liquidity, which is expected to have an additional positive impact on the discount of the New Ordinary Shares. Conditional on the Consolidation, which requires the approval of the Company's shareholders, the Board also intends to introduce the following features which it believes will further appeal to investors:

1. Introduction of an enhanced income strategy to target a dividend of 4% p.a. (based on the net asset value of the New Ordinary Shares as at the end of the preceding financial year) - such strategy is differentiated to other European investment companies and makes use of the closed-ended structure;

2. Adoption of an active discount management policy with a commitment to keep any discount on the New Ordinary Shares to single digit levels, in normal market conditions;

3. Introduction of a performance-related tender offer - if NAV total return performance is behind the Company's benchmark (the MSCI Europe ex UK Index (total return) in sterling terms) over a five year period from Consolidation, a tender offer will be made for up to 25% of the outstanding share capital at NAV less costs;

4. Lower management fees - a reduced fee calculated on net assets of 0.55% p.a. up to £400m, 0.4% p.a. thereafter;

5. Reduction of the notice period to 6 months (from 12 months at present); and

6. Change of the Company's name to JPMorgan European Growth & Income plc, with the New Ordinary shares trading under a new ticker, JEGI.

The Company has consulted with shareholders representing material interests in both the Income Shares and the Growth Shares and they have indicated their support for these proposals. The Company expects to publish a circular and notice of meeting(s) in connection with the Consolidation in due course and aims, subject to approval of the Company's shareholders, to conclude the Consolidation and to introduce the above features by late 2021/early 2022.

 

For further information please contact:

 

JPMorgan Funds Limited

Tim Mitchell - 0207 742 8879

Winterflood Securities LimitedNeil Morgan - 020 3100 0292

 

The person responsible for arranging for the release of this announcement on behalf of the Company is Paul Winship of JPMorgan Funds Limited.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBLBDGCDBDGBC
Date   Source Headline
16th Mar 202112:02 pmRNSNet Asset Value(s)
15th Mar 20215:10 pmRNSTransaction in Own Shares
15th Mar 202112:07 pmRNSGearing Announcement
15th Mar 202111:23 amRNSNet Asset Value(s)
12th Mar 20215:11 pmRNSTransaction in Own Shares
12th Mar 20212:14 pmRNSTen Largest Investments
12th Mar 202110:32 amRNSNet Asset Value(s)
11th Mar 20213:58 pmRNSShare Conversion
11th Mar 202111:07 amRNSNet Asset Value(s)
10th Mar 202110:41 amRNSNet Asset Value(s)
9th Mar 202110:37 amRNSNet Asset Value(s)
8th Mar 20214:49 pmRNSHolding(s) in Company
8th Mar 202111:50 amRNSGearing Announcement
8th Mar 202111:08 amRNSNet Asset Value(s)
5th Mar 202111:13 amRNSNet Asset Value(s)
4th Mar 202110:56 amRNSNet Asset Value(s)
3rd Mar 202110:37 amRNSNet Asset Value(s)
2nd Mar 20215:30 pmRNSTransaction in Own Shares
2nd Mar 202111:06 amRNSNet Asset Value(s)
1st Mar 20215:30 pmRNSTransaction in Own Shares
1st Mar 20211:11 pmRNSGearing Announcement
1st Mar 20211:05 pmRNSNet Asset Value(s)
26th Feb 20215:25 pmRNSTotal Voting Rights
26th Feb 20215:11 pmRNSTransaction in Own Shares
26th Feb 202111:21 amRNSNet Asset Value(s)
25th Feb 20216:19 pmRNSDirector/PDMR Shareholding
25th Feb 20215:25 pmRNSTransaction in Own Shares
25th Feb 202111:06 amRNSNet Asset Value(s)
24th Feb 20215:16 pmRNSTransaction in Own Shares
24th Feb 202110:26 amRNSNet Asset Value(s)
23rd Feb 20215:25 pmRNSTransaction in Own Shares
23rd Feb 202111:28 amRNSNet Asset Value(s)
22nd Feb 20215:19 pmRNSTransaction in Own Shares
22nd Feb 202111:17 amRNSGearing Announcement
22nd Feb 202110:54 amRNSNet Asset Value(s)
19th Feb 202111:09 amRNSNet Asset Value(s)
18th Feb 202110:47 amRNSNet Asset Value(s)
17th Feb 20215:07 pmRNSTransaction in Own Shares
17th Feb 202110:45 amRNSNet Asset Value(s)
16th Feb 20215:08 pmRNSTransaction in Own Shares
16th Feb 202111:05 amRNSNet Asset Value(s)
15th Feb 20214:14 pmRNSTop Ten Holdings
15th Feb 202112:14 pmRNSNet Asset Value(s)
15th Feb 202112:10 pmRNSGearing Announcement
15th Feb 20218:58 amRNSDirectorate Change
12th Feb 20219:57 amRNSNet Asset Value(s)
12th Feb 20217:00 amRNSDividend Declaration
11th Feb 202110:57 amRNSNet Asset Value(s)
10th Feb 202110:08 amRNSNet Asset Value(s)
9th Feb 202110:50 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.